Skip to main content

Advertisement

Table 2 aPS/PT IgG/IgM, aPL IgG/IgM, and ATI IgG during the anti-TNFa treatment of 30 IBD patients with infliximab

From: Phosphatidylserine-dependent anti-prothrombin antibodies (aPS/PT) in infliximab-treated patients with inflammatory bowel diseases

  W2 n (%) W14 n (%)
aPS/PT IgG 9 (30 %) 3 (10 %)
aPS/PT IgM 0 0
aPS/PT IgG and IgM 3 (10 %) 2 (6.7 %)
aPL IgG 1 (3.3 %) 1 (3.3 %)
aPL IgM 4 (13.3 %) 4 (13.3 %)
aPL IgG and IgM 0 0
ATI IgG 2 (6.7 %) 6 (20 %)
  1. aPS/PT phosphatidylserine-dependent anti-prothrombin antibodies, aPL antiphospholipid antibodies, ATI antibodies to infliximab, W2 second week of the biological treatment, W14 14th week of the biological treatment